HanAll Biopharma Announces Orphan Drug Designation for Batoclimab in Japan for Active Thyroid Eye Disease
HanAll Biopharma Co., Ltd. (KRX: 009420.KS), a global biopharmaceutical company committed to discovering and developing ...
Targeted Oncology4d
FDA Grants Bexmarilimab Orphan Drug Designation for MDS
The investigational immunotherapy bexmarilimab has been granted orphan drug designation from the FDA for patients with ...
Contract Pharma3d
ENCell’s EN001 Granted Orphan Drug Designation by FDA
ENCell’s investigational drug EN001 has been granted Orphan Drug Designation by the FDA for the treatment of ...
DiagnaMed Granted FDA Orphan Drug Designation for Molecular Hydrogen to Treat Amyotrophic Lateral Sclerosis
Detailed price information for Diagnamed Holdings Corp. (DMED-CN) from The Globe and Mail including charting and trades.
Targeted Oncology2d
FDA Grants Rhenium Obisbemeda Orphan Drug Status for LM in Lung Cancer
The FDA granted orphan drug status to rhenium-186 obisbemeda for treating leptomeningeal metastases in lung cancer.
Plus Therapeutics soars on FDA Orphan Drug Designation for lung cancer treatment
Plus Therapeutics (PSTV) stock soars with FDA's Orphan Drug Designation for Rhenium Obisbemeda, targeting rare leptomeningeal metastases. Read more here.
Plus Therapeutics granted Orphan Drug Designation for Rhenium Obisbemeda
Plus Therapeutics (PSTV) announces that the U.S. Food and Drug Administration has granted Orphan Drug Designation to Rhenium Obisbemeda for the ...
The US FDA Grants Both Orphan Drug and Rare Pediatric Disease Designations to NEU-001 of Neurenati for the Treatment of Hirschsprung Disease
Neurenati Therapeutics Inc., a biotech company focused on rare pediatric diseases, is pleased to announce that the U.S. Food ...
Business Wire3d
ENCell’s EN001 Receives Orphan Drug Designation from the U.S. FDA for Charcot-Marie-Tooth Disease
EN001, a novel therapy under development by ENCell, has been granted Orphan Drug Designation by the U.S. FDA for the treatment of Charcot-Marie-Tooth (CMT) disease. Phase 1 clinical trial confirmed ...
Plus Therapeutics Continues Rally On Friday - Here's Why
Plus Therapeutics stock rises after peer-reviewed publication of Phase 1 glioma data and FDA Orphan Drug Designation for lung ...